PHIBRO ANIMAL HEALTH CORP
PAHC evidence brief
What we can confirm
- BioSniper Score:
- 0.7 / 10
- Market Cap:
- $1.51B
What it means
What to watch
Prepared research question
What matters most for PAHC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PAHC
PHIBRO Animal Health Corporation is a global diversified animal health and mineral nutrition company that develops, manufactures, and markets products for food animals, companion animals, and select industrial applications [sec_mda · as of 2026-08-26].
Key risk: High debt leverage
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$1.51B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
PHIBRO Animal Health Corporation is a global diversified animal health and mineral nutrition company that develops, manufactures, and markets products for food animals, companion animals, and select industrial applications [sec_mda · as of 2026-08-26].
- Cash & equivalents of $61.4M, shareholders' equity of $385.5M, and total debt of $737.9M as of 2026-06-30 [sec].
- Markets approximately 790 product lines in roughly 90 countries [sec_mda · as of 2026-08-26].
- Launched Restoris® canine dental device in October 2025 and Rejensa® joint care supplement gained market traction in fiscal year 2026 [sec_mda · as of 2026-08-26].
- Operates autogenous vaccine and adjuvant production capacity in Omaha, Nebraska, and launched a new vaccine facility in Guarulhos, Brazil in 2023 [sec_mda · as of 2026-08-26].
What works
- Broad global footprint with approximately 790 product lines in about 90 countries provides geographic diversification [sec_mda · as of 2026-08-26].
- Active innovation pipeline includes new product launches (e.g., Restoris® canine dental device) and advancing microbial and bioproduct development programs [sec_mda · as of 2026-08-26].
- Manufacturing investments, such as the 2023 vaccine facility in Brazil, support capacity for autogenous vaccines for swine, poultry, and aquaculture [sec_mda · as of 2026-08-26].
What to weigh
- Total debt of $737.9M significantly exceeds shareholders' equity of $385.5M as of 2026-06-30, indicating high leverage [sec].
- Outbreaks of animal diseases could significantly reduce demand for products or availability of raw materials [sec_mda · as of 2026-05-06].
- Restrictions on the use of antibacterials in food-producing animals may become more prevalent, potentially impacting product sales [sec_mda · as of 2026-05-06].
- Failure of product approval, R&D, acquisition, and licensing efforts to generate new products is a stated risk [sec_mda · as of 2026-05-06].
From the filings
Quoted directly from source documents.
Company description and global reach
“Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We develop, manufacture and market a broad range of products for food animals including poultry, beef and dairy cattle, swine, aquaculture and dogs.”
SEC MD&A · August 26, 2026
Product line count and geographic presence
“We market approximately 790 product lines in approximately 90 countri”
SEC MD&A · August 26, 2026
Recent companion animal product launches
“in October 2025, we launched Restoris®, a new canine dental device, and in fiscal year 2026, our Rejensa®joint care supplement continued to gain market traction.”
SEC MD&A · August 26, 2026
Risk of animal disease outbreaks affecting demand
“outbreaks of animal diseases could significantly reduce demand for our products or availability of raw materials;”
SEC MD&A · May 6, 2026
Catalyst timeline
- 2026-08-26 · Earnings: Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2026 Results — The company expects to announce its fourth quarter and fiscal year 2026 financial results on this date.
Risks & what to watch (4)›
Key risks
- High debt leverage — Total debt of $737.9M exceeds shareholders' equity of $385.5M as of 2026-06-30 [sec].
- Animal disease outbreaks — Outbreaks could significantly reduce product demand or raw material availability [sec_mda · as of 2026-05-06].
- Regulatory restrictions on antibacterials — Restrictions on antibacterial use in food animals may become more prevalent, impacting sales [sec_mda · as of 2026-05-06].
- R&D and product approval failure — Failure to generate new products through R&D, acquisition, or licensing is a stated risk [sec_mda · as of 2026-05-06].
What to watch
- Fourth quarter and fiscal year 2026 financial results expected on August 26, 2026 [catalyst].
- Progress of microbial and bioproduct development programs for animal health, environmental resilience, and industrial performance [sec_mda · as of 2026-08-26].
- Regulatory developments regarding antibacterial use restrictions in food-producing animals [sec_mda · as of 2026-05-06].
Sources: Catalysts · Competitor trials · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run PHIBRO ANIMAL HEALTH CORP through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PHIBRO ANIMAL HEALTH CORP facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 2.89
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
1 buy · 21 sells (180d)
Financials
Short Interest
as of May 22, 2026- % of float
- 6.9%
- Days to cover
- 4.6
- Shares short
- 1,215,037
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PAHC short interestGovernance
Frequently asked questions
What is the AI investment thesis for PHIBRO ANIMAL HEALTH CORP?
PHIBRO Animal Health Corporation is a global diversified animal health and mineral nutrition company that develops, manufactures, and markets products for food animals, companion animals, and select industrial applications [sec_mda · as of 2026-08-26].
Who is the CEO of PHIBRO ANIMAL HEALTH CORP?
Mr. Daniel M. Bendheim J.D. is the chief executive officer of PHIBRO ANIMAL HEALTH CORP (PAHC).
Where is PHIBRO ANIMAL HEALTH CORP headquartered?
PHIBRO ANIMAL HEALTH CORP (PAHC) is headquartered in Teaneck, NJ, United States.
What therapeutic areas does PHIBRO ANIMAL HEALTH CORP focus on?
PHIBRO ANIMAL HEALTH CORP develops therapies across Pain, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.